77-16-7
Chemical Structure
Plumericin
- CAS No.: 77-16-7
- Formula:C15H14O6
- Molecular Weight:290.27
IUPAC Name: methyl (3aR,3a1S,4aS,7aS,9aS,E)-5-ethylidene-6-oxo-3a1,4a,5,9a-tetrahydro-3aH,6H-3,4,7-trioxadicyclopenta[a,hi]indene-1-carboxylate
InChIKey: VFXXNAVZODKBIW-JKXVGBJFSA-N
SMILES: C(\C)=C/1\[C@]2([C@]3([C@@]4([C@](C=C3)(C(C(OC)=O)=CO[C@@]4(O2)[H])[H])[H])OC1=O)[H]
Biological Activity: Plumericin is an anti-inflammatory, antioxidant, and antibacterial agent. Plumericin reduces Apoptosis, promotes Nrf-2 and inhibits NF-κB and AhR activation, blocks STAT3 signaling. Plumericin inhibits Mycobacterium tuberculosis growth. Plumericin can be used for the research of chronic kidney disease, vascular diseases, inflammatory bowel diseases, peritonitis, and tuberculosis[1][2][3][4][5][6].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Plumericin | Plumericin is an anti-inflammatory, antioxidant, and antibacterial agent. Plumericin reduces Apoptosis, promotes Nrf-2 and inhibits NF-κB and AhR activation, blocks STAT3 signaling. Plumericin inhibits Mycobacterium tuberculosis growth. Plumericin can be used for the research of chronic kidney disease, vascular diseases, inflammatory bowel diseases, peritonitis, and tuberculosis. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Rispoli RM, et al. Plumericin Modulates the AhR-NFκB-Nrf2 Signaling Network to Counteract Indoxyl Sulfate-Induced Intestinal Epithelial Cells Impairment. Int J Mol Sci. 2025;27(1):293. Published 2025 Dec 27. [Content Brief]
- [2]. Heiss EH, et al. Plumericin inhibits proliferation of vascular smooth muscle cells by blocking STAT3 signaling via S-glutathionylation. Sci Rep. 2016;6:20771. Published 2016 Feb 9. [Content Brief]
- [3]. Rapa SF, et al. Plumericin prevents intestinal inflammation and oxidative stress in vitro and in vivo. FASEB J. 2020;34(1):1576-1590. [Content Brief]
- [4]. Fakhrudin N, et al. Identification of plumericin as a potent new inhibitor of the NF-κB pathway with anti-inflammatory activity in vitro and in vivo. Br J Pharmacol. 2014;171(7):1676-1686. [Content Brief]
- [5]. Rapa SF, et al. Plumericin Protects against Experimental Inflammatory Bowel Disease by Restoring Intestinal Barrier Function and Reducing Apoptosis. Biomedicines. 2021;9(1):67. Published 2021 Jan 12. [Content Brief]
- [6]. Kumar P, et al. Anti-mycobacterial activity of plumericin and isoplumericin against MDR Mycobacterium tuberculosis. Pulm Pharmacol Ther. 2013;26(3):332-335. [Content Brief]
Keywords
